Evidence mounts for the efficacy of radioimmunotherapy for B-cell lymphomas

Editorial

Oliver W Press. J Clin Oncol. 2008.

. 2008 Nov 10;26(32):5147-50.

doi: 10.1200/JCO.2008.18.5447. Epub 2008 Oct 14.

No abstract available

Comment in

Hematologic toxicity and double autografting of stem cells after myeloablative activities of yttrium-90-ibritumomab tiuxetan.
Vanazzi A, Cremonesi M, Paganelli G, Martinelli G. Vanazzi A, et al. J Clin Oncol. 2009 Mar 1;27(7):1145-6; author reply 1146. doi: 10.1200/JCO.2008.20.8769. Epub 2009 Jan 26. J Clin Oncol. 2009. PMID: 19171699 No abstract available.

Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma.
Morschhauser F, Radford J, Van Hoof A, Vitolo U, Soubeyran P, Tilly H, Huijgens PC, Kolstad A, d'Amore F, Gonzalez Diaz M, Petrini M, Sebban C, Zinzani PL, van Oers MH, van Putten W, Bischof-Delaloye A, Rohatiner A, Salles G, Kuhlmann J, Hagenbeek A. Morschhauser F, et al. J Clin Oncol. 2008 Nov 10;26(32):5156-64. doi: 10.1200/JCO.2008.17.2015. Epub 2008 Oct 14. J Clin Oncol. 2008. PMID: 18854568 Clinical Trial.
High-dose yttrium-90-ibritumomab tiuxetan with tandem stem-cell reinfusion: an outpatient preparative regimen for autologous hematopoietic cell transplantation.
Devizzi L, Guidetti A, Tarella C, Magni M, Matteucci P, Seregni E, Chiesa C, Bombardieri E, Di Nicola M, Carlo-Stella C, Gianni AM. Devizzi L, et al. J Clin Oncol. 2008 Nov 10;26(32):5175-82. doi: 10.1200/JCO.2008.16.8294. Epub 2008 Oct 14. J Clin Oncol. 2008. PMID: 18854569 Clinical Trial.

1. Morschhauser F, Radford J, Van Hoof A, et al: Phase III trial of consolidation therapy with yttrium-90–ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol doi: 10.1200/JCO.2008.17.2015 [epub ahead of print on October 13, 2008] - DOI - PubMed
1. Devizzi L, Guidetti A, Tarella C, et al: High-dose yttrium-90–ibritumomab tiuxetan with tandem stem-cell reinfusion: An outpatient preparative regimen for autologous hematopoietic cell transplantation. J Clin Oncol doi: 10.1200/JCO.2008.16.8294 [epub ahead of print on October 13, 2008] - DOI - PubMed
1. DeNardo GL, DeNardo SJ, Goldstein DS, et al: Maximum-tolerated dose, toxicity, and efficacy of (131)I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma. J Clin Oncol 16:3246-3256, 1998 - PubMed
1. Kaminski MS, Zasadny KR, Francis IR, et al: Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody. N Engl J Med 329:459-465, 1993 - PubMed
1. Witzig TE, Gordon LI, Cabanillas F, et al: Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 20:2453-2463, 2002 - PubMed